Bet_Noire
Mizuho has downgraded Relmada Therapeutics (NASDAQ:RLMD) to neutral on the apparent demise of its drug candidate REL-1017 for major depressive disorder.
The investment bank said it was disappointed that a Data Monitoring Committee determined a Phase 3 study for the